Adding Vaccinex (VCNX) $5.50, to Watch List After Investor Presentation.
IPO Tumbles in Aftermarket, from $12 underwritten by Oppenheimer, BTIG and Ladenburg Thalmann, to a low of $3 in six months.
HCN Network. Like Investing in Uber or Lyft, When They Only had 9,000 Drivers?
Internet Stock Review Report on Hotel Communications Network.
HCN Communication Network has the most exciting Internet Advertising...
Okay, so What’s Next for Citius Pharma (CTXR) $1.16?
Dawson James Broker/Dealer Updates. Price Target Remains at $7.00.
"OK, So what’s Next? Topline data from the superior efficacy...
New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.
Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...
Adding American BriVision (ABVC) $3.30 to Stocks We Expect Double List. $7.00 Price Potential.
Adding to Our 2020 Biotech 5-Pack, 5 Stocks We Expect to Double in 2020
Dow 36,000 – S&P 500 4,500 – NASDAQ 15,000. Then a Crash. David Hunter.
David Hunter, chief macro strategist at Contrarian Macro Advisors.
Interesting interview with David Hunter, who predicts some awful things...
Video: What to Look for in Public Company Management.
In this episode MicroCapClub interviews author and fund manager Michael Shearn.
Michael discusses management teams that focus on solving...
Hollywood Stock Review Adds SLS Audio to Watch List
CLICK TO READ
RESEARCH REPORT
Asia-Pacific: A Region of Stability Amidst Economic Uncertainty
Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE